Halozyme's pancreatic cancer drug succeeds in mid-stage trial

Jan 5 (Reuters) - Halozyme Therapeutics Inc said

its lead drug to treat a late form of pancreated cancer met the

main goal in a mid-stage study, sending its shares soaring in

premarket trading.

Read more